P/E ratio for CONMED (CNMD)
P/E ratio as of July 2025 (TTM): 12.5
According to CONMED's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 12.5182. At the end of 2024 the company had a P/E ratio of 16.0.
P/E ratio history for CONMED from 2001 to 2025
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2024 | 16.0 | -69.26% |
| 2023 | 51.9 | -261.6% |
| 2022 | -32.1 | -148.48% |
| 2021 | 66.2 | -80.48% |
| 2020 | 339 | 209.56% |
| 2019 | 110 | 149.33% |
| 2018 | 44.0 | 71.68% |
| 2017 | 25.6 | -69.85% |
| 2016 | 84.9 | 112.11% |
| 2015 | 40.0 | 5.1% |
| 2014 | 38.1 | 16.55% |
| 2013 | 32.7 | 67.26% |
| 2012 | 19.5 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Boston Scientific BSX | 74.5 | 495.28% | 🇺🇸 USA |
 Smith & Nephew
SNN | 26.8 | 114.09% | 🇬🇧 UK |
 Teleflex TFX | 34.6 | 176.31% | 🇺🇸 USA |
 Medtronic MDT | 27.1 | 116.44% | 🇮🇪 Ireland |
 Integra LifeSciences IART | -29.7 | -337.33% | 🇺🇸 USA |
 Stryker Corporation SYK | 51.9 | 314.21% | 🇺🇸 USA |
 Johnson & Johnson JNJ | 18.1 | 44.66% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.